The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated
